This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Stock Market News for Feb 15, 2022
by Zacks Equity Research
Wall Street lower on Monday as geopolitical tensions between Russia and Ukraine intensified.
MRNANegative Net Change
biotechnology
Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?
by Kinjel Shah
Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.
GSKNegative Net Change PFENegative Net Change BEAMNegative Net Change BNTXNegative Net Change
biotechnology
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
LLYPositive Net Change VRTXNegative Net Change PRQRNegative Net Change VIRNegative Net Change
biotechnology pharmaceuticals
5 Lucrative GARP Stocks With Discounted PEG
by Urmimala Biswas
Here are the stocks, PFE, TECL, NXPI, EQNR and KBH based on discounted PEG.
PFENegative Net Change NXPINegative Net Change KBHNegative Net Change TECKPositive Net Change EQNRPositive Net Change
alt-energy biotechnology biotechs medical pharmaceuticals reit semiconductor
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
BIIBNegative Net Change AMGNNegative Net Change GILDNegative Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change
biotechnology biotechs etfs
Vir (VIR) Announces Encouraging Data on COVID-19 Antibody
by Zacks Equity Research
Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.
REGNNegative Net Change GSKNegative Net Change LLYPositive Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
by Zacks Equity Research
Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.
REGNNegative Net Change SNYNegative Net Change VRTXNegative Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
by Zacks Equity Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
REGNNegative Net Change BIIBNegative Net Change BMYNegative Net Change AMGNNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Should You Buy Phillips 66 (PSX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PSXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy OMV AG (OMVJF) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OMVJFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MSBINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat
by Mark Vickery
After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.
BPPositive Net Change PFENegative Net Change AMGNNegative Net Change TTWONegative Net Change CHGGPositive Net Change
biotechnology consumer-discretionary earnings software tech-stocks
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFENegative Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
BMYNegative Net Change PFENegative Net Change VRTXNegative Net Change VIRNegative Net Change
biotechnology biotechs
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
REGNNegative Net Change SNYNegative Net Change BIIBNegative Net Change GILDNegative Net Change MRNANegative Net Change
biotechnology medical pharmaceuticals
After Golden Cross, Tenaris S.A. (TS)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
by Zacks Equity Research
Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology biotechs earnings pharmaceuticals
4 Top Biotech Stocks to Gain Amid Industry Challenges
by Ekta Bagri
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
REGNNegative Net Change DVAXNegative Net Change VRTXNegative Net Change RGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Stocks With Recent Price Strength Amid Wall Street Turmoil
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.
ADMNegative Net Change VRTXNegative Net Change HAFCPositive Net Change DACNegative Net Change ESTENegative Net Change
agriculture biotechnology finance oil-energy transportation
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
BMYNegative Net Change PFENegative Net Change AMGNNegative Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Earnings Data to Flood Wall Street This Week
by Zacks Equity Research
Earnings Data to Flood Wall Street This Week.
AMZNNegative Net Change CVXPositive Net Change ADPNegative Net Change NFLXNegative Net Change MRNANegative Net Change FBPositive Net Change GOOGLNegative Net Change ETSYPositive Net Change
biotechnology business-services consumer-discretionary oil-energy tech-stocks
Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
REGNNegative Net Change SNYNegative Net Change PFENegative Net Change AMGNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
REGNNegative Net Change BIIBNegative Net Change RHHBYNegative Net Change ALKSNegative Net Change
biotechnology
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
PFENegative Net Change AMGNNegative Net Change GILDNegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings pharmaceuticals
After Golden Cross, NexTier Oilfield Solutions (NEX)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines